Enhanced Packaging and Reformulations Give New Life to Biologics - As the biotherapeutics market continues to grow, manufacturers focus on improving commercially available products. - BioPharm

ADVERTISEMENT

Enhanced Packaging and Reformulations Give New Life to Biologics
As the biotherapeutics market continues to grow, manufacturers focus on improving commercially available products.


BioPharm International
Volume 19, Issue 10


Tom Polen
The market for biotherapeutics has grown significantly since the first biologic drug was launched over 50 years ago. More than 250 biologic molecules have been developed and launched since 1996, and today biologics account for nearly 30% of compounds in the drug-development pipeline.




Recently, research and development (R&D) resources have focused not only on new molecular entities but also on improvements to commercially available products. Reformulations now comprise nearly 50% of new drug application (NDA) approvals at the US Food and Drug Administration (FDA).2 At drug-delivery companies focusing on injectable therapeutics, over 50% of the molecules in the pipelines are biologics, with many projects focused on developing sustained-release formulations.3

The challenge for drug makers, however, is to bring about these improvements while addressing the added packaging, manufacturing, and formulation challenges inherent in biologics, due to their unique sizes, structures, and stability profiles. More than 95% of large molecules are administered either through intravenous (IV) infusion or through subcutaneous injection,4 routes of administration that are highly efficacious yet undesirable to many patients. As a result, new technologies continue to emerge to improve administration and storage of these molecules.

ENHANCED PACKAGING AND FORMULATION STRATEGIES


Table 1. Selected packaging and formulation strategies for differentiating biologics
Life cycle management through enhanced packaging and newer drug-delivery technologies may ensure that a biologic compound's commercial potential is fully realized and that drug makers can stay ahead or at parity with the competition. Depending on a company's situation and time frame, a number of improvements can manage a product's life cycle (Table 1).

In the short term, drug makers are moving toward enhanced packaging that allows for safer, more intuitive reconstitution of lyophilized powder formulations and less complicated administration of biologics.

Mid-range improvements typically involve improved drug-delivery devices, a substantial growth area for drug manufacturers. Industry analysts predict that over the next three to four years the sale of biologics packaged with a device will show higher growth than the same product packaged alone, driven by the market appeal of devices that make administration of biologics easier.4


Quick Recap
Long-term improvements involve reformulations to reduce the frequency of administration or to enable less invasive treatment, such as pulmonary inhalation.

The best approach for a particular biologic compound depends on the molecule's market environment, point of use, and the company's short- and long-term strategy for its product and business.

SOLUTIONS FOR SUBCUTANEOUS AND INTRAMUSCULAR INJECTABLES

Today approximately 75% of biologics are administered via subcutaneous or intramuscular injection.4 Most recent advancements in drug-delivery technologies related to injectable biologics have focused on devices and technologies that improve safety, patient compliance, and convenience in both administration and storage.

6–18 Months

Short-term strategies primarily deliver improvements in convenience, compliance, or improved safety for healthcare workers as well as patients.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines
Source: BioPharm International,
Click here